Rgenix, Inc., a clinical stage biopharmaceutical company developing small molecule and antibody cancer therapeutics, raised $40 million in a Series C financing round led by Lepu Medical, a publicly traded global healthcare firm, Oceanpine Capital, and WuXi AppTec’s Corporate Venture Fund. Existing investors Novo Holdings
RenovoRx, Inc., a medical technology company developing a catheter-based approach to treating pancreatic cancer, closed a $10 million financing round led by Boston Scientific, btov Partners, and existing investors Astia Angels, the Angels' Forum, the Halo Fund III, L.P., Golden Seeds, and Acorn Campus Taiwan.
OncoNano Medicine, Inc., closed a $11.7 million Series A financing transaction arranged by Salem Partners, who also participated as a principal investor. The Series A funding supplements a $6 million grant previously received from the Cancer Prevention and Research Institute of Texas . OncoNano uses
Tempus announced the completion of $130 million in Series C financing led by New Enterprise Associates and Revolution Growth. Tempus is a technology company that is building the world’s largest library of molecular and clinical data and an operating system to make that data accessible and